Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis

2008 ◽  
Vol 26 (32) ◽  
pp. 5227-5232 ◽  
Author(s):  
Andrew L. Cooke ◽  
Colleen Metge ◽  
Lisa Lix ◽  
Heather J. Prior ◽  
William D. Leslie
Keyword(s):  
Fracture Risk ◽  
Osteoporotic Fracture ◽  
Case Control Study ◽  
Substantial Reduction ◽  
Osteoporotic Fractures ◽  
Population Based ◽  
Case Control ◽  
Mineral Density ◽  
Medical Diagnoses ◽  
Control Study

Purpose Although tamoxifen has been shown to increase bone mineral density in clinical trials, it is less clear whether this significantly affects fracture rates. Even fewer data are available on skeletal outcomes when tamoxifen is used outside of the context of a clinical trial. A population-based case-control study was undertaken to determine whether tamoxifen use is associated with osteoporotic fractures in routine clinical practice. Patients and Methods Population-based administrative data for the Province of Manitoba, Canada, were examined for tamoxifen use and nontraumatic fracture codes in women 50 years of age or older. Women with osteoporotic fractures (vertebral, wrist or hip; n = 11,096) from 1996 to 2004 were each compared with three controls without fracture, matched for age, ethnicity, and comorbidity (n = 33,209). Tamoxifen use was classified as never, past use, or current use. Results Lower osteoporotic fracture rates were associated with current tamoxifen use (univariate odds ratio [OR] = 0.68; 95% CI, 0.55 to 0.84). After controlling for demographic and medical diagnoses known to affect fracture risk, current use was associated with a significantly reduced overall osteoporotic fracture risk (adjusted OR = 0.68; 95% CI, 0.55 to 0.88) and of hip fractures (adjusted OR = 0.47; 95% CI, 0.28 to 0.77). Neither recent nor remote past tamoxifen use was associated with reduced osteoporotic fracture risk. Breast cancer was not independently associated with osteoporotic fractures (adjusted OR = 0.95; 95% CI, 0.81 to 1.12). Conclusion In a population-based case-control study, current tamoxifen use was associated with a substantial reduction in osteoporotic fractures.

Hip fracture risk in statin users?a population-based Danish case-control study

2004 ◽  
Vol 15 (6) ◽  
Author(s):  
Lars Rejnmark ◽  
MetteLena Olsen ◽  
S�renPaaske Johnsen ◽  
Peter Vestergaard ◽  
HenrikToft S�rensen ◽  
...  
Keyword(s):  
Hip Fracture ◽  
Fracture Risk ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Hip Fracture Risk ◽  
Control Study

Abstract P399: Cardiovascular and Non-Cardiovascular Disease Associations with Hip Fractures in the Elderly: A Population-Based Case-Control Study

Circulation ◽  
2012 ◽  
Vol 125 (suppl_10) ◽  
Author(s):  
Yariv Gerber ◽  
L. J Melton ◽  
Sheila M McNallan ◽  
Ruoxiang Jiang ◽  
Susan A Weston ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Heart Disease ◽  
Hip Fracture ◽  
Fracture Risk ◽  
Case Control Study ◽  
Metabolic Diseases ◽  
Population Based ◽  
Case Control ◽  
Community Control ◽  
Control Study

Background: There is growing awareness of an association between cardiovascular disease (CVD) and fractures, and a temporal increase in fracture risk after myocardial infarction has been noted but the mechanisms are not delineated. To evaluate this relationship, we systematically examined the association of hip fracture with all disease categories and assessed related secular trends. Methods: Using resources of the Rochester Epidemiology Project, a population-based incident case-control study was conducted. Disease history was compared between all Olmsted County, Minnesota, residents aged 50 years or older with a first hip fracture in 1985–2006 and community control subjects individually matched (1:1) to cases on age, sex, and index year (n=3,808; mean age [SD], 82 [9] years; 76% women). Results: All CVD and numerous non-CVD categories (e.g., infectious diseases, nutritional and metabolic diseases, mental disorders, diseases of the nervous system and sense organs, and diseases of the respiratory system) were associated with fracture risk. However, increasing temporal trends were almost exclusively detected in categories of CVD (Figure). The largest increases in association were observed for ischemic heart disease, other forms of heart disease (including heart failure), hypertension, and diabetes and were more pronounced among elderly women than other demographic groups. Conclusions: While the association with hip fracture was not specific to CVD, temporal increases were mainly detected in cardio-metabolic diseases, all of which have also been linked previously to frailty. This could delineate a common pathway that warrants further investigation.

Statins and hip fracture risk in men: a population-based case-control study

2015 ◽  
Vol 25 (11) ◽  
pp. 844-848 ◽  
Author(s):  
Annette L. Adams ◽  
Jiaxiao M. Shi ◽  
Kristi Reynolds ◽  
Reina Haque ◽  
T. Craig Cheetham ◽  
...  
Keyword(s):  
Hip Fracture ◽  
Fracture Risk ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Hip Fracture Risk ◽  
Control Study

scholarly journals Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Joo-Hyun Park ◽  
Jessie Lee ◽  
Su-Yeon Yu ◽  
Jin-Hyung Jung ◽  
Kyungdo Han ◽  
...  
Keyword(s):  
Peptic Ulcer ◽  
Proton Pump ◽  
Osteoporotic Fracture ◽  
Claims Data ◽  
Case Control Study ◽  
Osteoporotic Fractures ◽  
Case Control ◽  
Ulcer Disease ◽  
Nested Case Control ◽  
Control Study

Abstract Background Patients with peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are more likely to receive long-term therapy with proton pump inhibitors (PPIs). This study aimed to investigate the risk of osteoporotic fractures in PPI users compared to histamine-2 receptor antagonist (H2RA) users and the association between fractures and the duration and regular use of PPI. Methods A population-based, nationwide nested case-control study from January 2006 to December 2015 was performed using Korean National Health Insurance Service claims data. We included patients ≥50 years of age, without previous fractures, newly prescribed with PPI or H2RA, and diagnosed with PUD or GERD from 2006 to 2015. Patients with osteoporotic fracture (n = 59,240) were matched with the non-fracture control group (n = 296,200) at a 1:5 ratio based on sex, age, cohort entry date, follow-up duration, and bisphosphonate use. The osteoporotic fractures were defined using the diagnostic codes of claims data (M80, M81, M82, M484, M485, S220, S221, S320, S327, S422, S423, S525, S526, S72). Results The higher the cumulative use of PPIs, the higher the osteoporotic fracture risk (P for trend < 0.001). The risk of osteoporotic fracture in the patients whose cumulative use of PPI was more than 1 year was higher than that of others (OR: 1.42, 95% CI: 1.32–1.52). Patients who regularly used PPI in the recent 1 year had a higher risk of osteoporotic fracture than exclusive H2RA users (OR: 1.37, 95% CI: 1.26–1.50). Conclusions The risk of osteoporotic fracture increased with the duration of PPI use, especially when PPI was used for ≥1 year and regularly in the recent 1 year.

scholarly journals Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study

2018 ◽  
Vol 13 (1) ◽  
Author(s):  
M. Amine Amiche ◽  
Shahab Abtahi ◽  
Johanna H. M. Driessen ◽  
Peter Vestergaard ◽  
Frank de Vries ◽  
...  
Keyword(s):  
Fracture Risk ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Cumulative Exposure ◽  
High Dose ◽  
Dose Oral ◽  
Oral Glucocorticoids ◽  
Control Study

Vitamin C, Vitamin B12, Folate and the Risk of Osteoporotic Fractures. A Case-Control Study

2007 ◽  
Vol 77 (6) ◽  
pp. 359-368 ◽  
Author(s):  
Martínez-Ramírez ◽  
Palma Pérez ◽  
Delgado-Martínez ◽  
Martínez-González ◽  
De la Fuente Arrillaga ◽  
...  
Keyword(s):  
Folic Acid ◽  
Vitamin C ◽  
Fracture Risk ◽  
Case Control Study ◽  
Serum Vitamin ◽  
Osteoporotic Fractures ◽  
Case Control ◽  
Vitamin B ◽  
Erythrocyte Folate ◽  
Control Study

Water-soluble vitamins influence the development of an adequate structure of bone tissue, but there is scant information relating them with osteoporotic fractures. We analyze whether serum vitamin C, vitamin B12, and erythrocyte folate, or dietary intake of vitamin C and folate, are related with osteoporotic fractures in the elderly. A hospital-based case-control study was carried out at the Hospital of Jaén (167 cases, 167 controls), Spain. Cases were defined as patients aged 65 or more years with a low-energy fracture. Controls were people without fracture, matched for age and sex with cases. Diet was assessed by a semi-quantitative food frequency questionnaire. Serum vitamin C was measured using high-performance liquid chromatography (HPLC). Folic acid and vitamin B12 were measured using procedures of competitive or immunometric immunoassay. Multivariable analyses were also fitted to adjust for confounding using analysis of covariance (for the comparison of adjusted means) and conditional logistic regression (for estimating adjusted odds ratios). A statistically significant difference between cases and controls for vitamin C blood levels was found, being higher for controls (p = 0.01). Analysis of the association between serum vitamin C and fracture risk showed a linear trend (p = 0.03) with a significantly reduced risk for the upper quartile (OR = 0.31; 95% CI 0.11–0.87). The intake of vitamin C, folic acid, and B12 was not related to fracture risk, nor was there any association with erythrocyte folate or serum vitamin B12. In conclusion, serum vitamin C levels were lower in cases with osteoporotic fractures than in controls.

Sign in / Sign up

Export Citation Format

Share Document